Generic Name and Formulations:
Latanoprostene bunod 0.024%; oph soln; contains benzalkonium chloride.
Valeant Pharmaceuticals, Inc
Indications for VYZULTA:
Open-angle glaucoma. Ocular hypertension.
>16yrs: instill 1 drop in the affected eye(s) once daily in the PM.
≤16yrs: not recommended.
Do not exceed recommended dose (may reduce efficacy). History of ocular inflammation: not recommended if active inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Bacterial keratitis may occur (due to multiple-dose containers). Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Allow at least 5mins between application of other topical oph agents.
Conjunctival hyperemia, eye irritation, eye pain, instillation site pain; increased ocular pigmentation (eg, iris [may be permanent], eyelid, eyelashes), other eyelash/lid changes, macular edema (including cystoid macular edema).
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force